103 related articles for article (PubMed ID: 12044033)
1. Towards optimal design of second-generation immunomodulatory oligonucleotides.
Kandimalla ER; Yu D; Agrawal S
Curr Opin Mol Ther; 2002 Apr; 4(2):122-9. PubMed ID: 12044033
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in immunostimulatory CpG oligonucleotides.
Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of immunostimulatory oligonucleotides.
Uhlmann E; Vollmer J
Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
[TBL] [Abstract][Full Text] [Related]
4. Enhancing immunogenicity by CpG DNA.
Jiang W; Pisetsky DS
Curr Opin Mol Ther; 2003 Apr; 5(2):180-5. PubMed ID: 12772509
[TBL] [Abstract][Full Text] [Related]
5. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
6. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
7. The immunostimulatory activity of CpG oligonucleotides on microglial N9 cells is affected by a polyguanosine motif.
Zhang Z; Guo K; Schluesener HJ
J Neuroimmunol; 2005 Apr; 161(1-2):68-77. PubMed ID: 15748945
[TBL] [Abstract][Full Text] [Related]
8. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments.
Ahmad-Nejad P; Häcker H; Rutz M; Bauer S; Vabulas RM; Wagner H
Eur J Immunol; 2002 Jul; 32(7):1958-68. PubMed ID: 12115616
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: CpG-7909, Coley.
Paul S
Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.
Kandimalla ER; Bhagat L; Li Y; Yu D; Wang D; Cong YP; Song SS; Tang JX; Sullivan T; Agrawal S
Proc Natl Acad Sci U S A; 2005 May; 102(19):6925-30. PubMed ID: 15860583
[TBL] [Abstract][Full Text] [Related]
11. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA.
Agrawal S; Kandimalla ER
Ann N Y Acad Sci; 2003 Dec; 1002():30-42. PubMed ID: 14751820
[TBL] [Abstract][Full Text] [Related]
13. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
14. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration.
Heikenwalder M; Polymenidou M; Junt T; Sigurdson C; Wagner H; Akira S; Zinkernagel R; Aguzzi A
Nat Med; 2004 Feb; 10(2):187-92. PubMed ID: 14745443
[TBL] [Abstract][Full Text] [Related]
15. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
16. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
Li Y; Kandimalla ER; Yu D; Agrawal S
Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
[TBL] [Abstract][Full Text] [Related]
17. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
18. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
[TBL] [Abstract][Full Text] [Related]
19. Immunostimulatory CpG oligonucleotides form defined three-dimensional structures: results from an NMR study.
He G; Patra A; Siegmund K; Peter M; Heeg K; Dalpke A; Richert C
ChemMedChem; 2007 Apr; 2(4):549-60. PubMed ID: 17366653
[TBL] [Abstract][Full Text] [Related]
20. Uptake, intracellular distribution, and novel binding proteins of immunostimulatory CpG oligodeoxynucleotides in microglial cells.
Zhang Z; Weinschenk T; Schluesener HJ
J Neuroimmunol; 2005 Mar; 160(1-2):32-40. PubMed ID: 15710455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
